|Drug||Therapeutic Area*||Biomarker†||Referenced |
|Tetrabenazine||Neurology||CYP2D6||CYP2D6 poor |
Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology
* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.